News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Idera Pharmaceuticals, Inc. Provides Update on Drug Candidate Pipeline Targeted to Toll-like Receptors
June 16, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today provided an update on its drug candidate pipeline targeted to Toll-like Receptors (TLRs) during its 2009 Annual Meeting of Stockholders.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
Phase II
MORE ON THIS TOPIC
Cystic fibrosis
Arcturus Plunges on ‘Mixed’ Cystic Fibrosis Data for Inhaled mRNA Drug
October 23, 2025
·
2 min read
·
Tristan Manalac
Vaccines
Moderna Scraps CMV Vaccine After Phase III Fail
October 23, 2025
·
3 min read
·
Tristan Manalac
Cancer
ADC, Bispecifics and Kinase Blockers Steal the Spotlight at ESMO 2025 in Berlin
October 22, 2025
·
4 min read
·
Tristan Manalac
Obesity
Terns Turns Away From Obesity Pill After ‘Uncompetitive’ Phase II Profile
October 22, 2025
·
2 min read
·
Tristan Manalac
